These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 18221147)
1. A mini-review of recent W.O. patents (2004-2005) of novel anti-fungal compounds in the field of anti-infective drug targets. Zhang W; Becker D; Cheng Q Recent Pat Antiinfect Drug Discov; 2006 Jun; 1(2):225-30. PubMed ID: 18221147 [TBL] [Abstract][Full Text] [Related]
2. Heat shock protein inhibitors for the treatment of fungal infections. Wirk B Recent Pat Antiinfect Drug Discov; 2011 Jan; 6(1):38-44. PubMed ID: 21192778 [TBL] [Abstract][Full Text] [Related]
3. Potential targets for the development of new antifungal drugs. Su H; Han L; Huang X J Antibiot (Tokyo); 2018 Nov; 71(12):978-991. PubMed ID: 30242283 [TBL] [Abstract][Full Text] [Related]
4. Newer patents in antimycotic therapy. Shahid SK Pharm Pat Anal; 2016; 5(2):115-34. PubMed ID: 26900731 [TBL] [Abstract][Full Text] [Related]
5. Sphingolipids as targets for treatment of fungal infections. Rollin-Pinheiro R; Singh A; Barreto-Bergter E; Del Poeta M Future Med Chem; 2016 Aug; 8(12):1469-84. PubMed ID: 27502288 [TBL] [Abstract][Full Text] [Related]
6. Chitin synthase inhibitors as antifungal agents. Chaudhary PM; Tupe SG; Deshpande MV Mini Rev Med Chem; 2013 Feb; 13(2):222-36. PubMed ID: 22512590 [TBL] [Abstract][Full Text] [Related]
7. Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review. Anusionwu CG; Aderibigbe BA; Mbianda XY Mini Rev Med Chem; 2019; 19(6):450-464. PubMed ID: 30526457 [TBL] [Abstract][Full Text] [Related]
9. Fungal sphingolipids as targets for the development of selective antifungal therapeutics. Thevissen K; Francois IE; Aerts AM; Cammue BP Curr Drug Targets; 2005 Dec; 6(8):923-8. PubMed ID: 16375675 [TBL] [Abstract][Full Text] [Related]
10. The 3-hydroxy-3-methylglutaryl coenzyme-A reductases from fungi: a proposal as a therapeutic target and as a study model. Andrade-Pavón D; Sánchez-Sandoval E; Rosales-Acosta B; Ibarra JA; Tamariz J; Hernández-Rodríguez C; Villa-Tanaca L Rev Iberoam Micol; 2014; 31(1):81-5. PubMed ID: 24270073 [TBL] [Abstract][Full Text] [Related]
11. Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Hasim S; Coleman JJ Future Med Chem; 2019 Apr; 11(8):869-883. PubMed ID: 30994368 [TBL] [Abstract][Full Text] [Related]
12. An overview of antifungal peptides derived from insect. Faruck MO; Yusof F; Chowdhury S Peptides; 2016 Jun; 80():80-88. PubMed ID: 26093218 [TBL] [Abstract][Full Text] [Related]
13. Targeting intrinsic cell death pathways to control fungal pathogens. Kulkarni M; Stolp ZD; Hardwick JM Biochem Pharmacol; 2019 Apr; 162():71-78. PubMed ID: 30660496 [TBL] [Abstract][Full Text] [Related]
16. Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review. Ribas E Ribas AD; Spolti P; Del Ponte EM; Donato KZ; Schrekker H; Fuentefria AM Braz J Microbiol; 2016; 47(4):793-799. PubMed ID: 27544394 [TBL] [Abstract][Full Text] [Related]
20. The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies. Reales-Calderón JA; Molero G; Gil C; Martínez JL Future Med Chem; 2016 Aug; 8(12):1503-20. PubMed ID: 27485839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]